The Business of RNAi Therapeutics in 2012
Open Access
- 1 January 2012
- journal article
- Published by Elsevier BV in Molecular Therapy Nucleic Acids
- Vol. 1 (2), e8
- https://doi.org/10.1038/mtna.2011.9
Abstract
No abstract availableThis publication has 45 references indexed in Scilit:
- RNAi-based Therapeutics Targeting Survivin and PLK1 for Treatment of Bladder CancerMolecular Therapy, 2011
- Suppression and Replacement Gene Therapy for Autosomal Dominant Disease in a Murine Model of Dominant Retinitis PigmentosaMolecular Therapy, 2011
- Substrate-Specific Kinetics of Dicer-Catalyzed RNA ProcessingJournal of Molecular Biology, 2010
- Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAsNature Biotechnology, 2009
- Asymmetric Shorter-duplex siRNA Structures Trigger Efficient Gene Silencing With Reduced Nonspecific EffectsMolecular Therapy, 2009
- Sequence- and target-independent angiogenesis suppression by siRNA via TLR3Nature, 2008
- Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathwaysNature, 2006
- Synthetic shRNAs as potent RNAi triggersNature Biotechnology, 2004
- Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacyNature Biotechnology, 2004
- Expression profiling reveals off-target gene regulation by RNAiNature Biotechnology, 2003